Experimentally, PT was proven as a potent ERS activator against esophageal cancer via inducing apoptosis-related cell death10, but the effects of ERS signaling in the anti-NSCLC actions of PT have not been examined. This evidence concerns the gene F2 and non-small cell lung carcinoma.